Recursion Pharmaceuticals (RXRX) Revenue & Revenue Breakdown
Recursion Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$44.58M
Latest Revenue (Q)
$13.79M
Main Segment (Y)
License and Service
Recursion Pharmaceuticals Revenue by Period
Recursion Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $44.58M | 12.33% |
| 2022-12-31 | $39.68M | 296.81% |
| 2021-12-31 | $10.00M | 193.00% |
| 2020-12-31 | $3.41M | 99.47% |
| 2019-12-31 | $1.71M | - |
Recursion Pharmaceuticals generated $44.58M in revenue during NA 2023, up 12.33% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Recursion Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $13.79M | 26.66% |
| 2023-12-31 | $10.89M | 7.81% |
| 2023-09-30 | $10.10M | -8.30% |
| 2023-06-30 | $11.02M | -9.21% |
| 2023-03-31 | $12.13M | -11.28% |
| 2022-12-31 | $13.68M | 4.77% |
| 2022-09-30 | $13.05M | 70.56% |
| 2022-06-30 | $7.65M | 44.42% |
| 2022-03-31 | $5.30M | 111.96% |
| 2021-12-31 | $2.50M | - |
| 2021-09-30 | $2.50M | - |
| 2021-06-30 | $2.50M | - |
| 2021-03-31 | $2.50M | -2.00% |
| 2020-12-31 | $2.55M | 195.94% |
| 2020-09-30 | $862.00K | 363.44% |
| 2020-06-30 | $186.00K | 210.00% |
| 2020-03-31 | $60.00K | - |
Recursion Pharmaceuticals generated $13.79M in revenue during Q1 2024, up 26.66% compared to the previous quarter, and up 100.86% compared to the same period a year ago.
Recursion Pharmaceuticals Revenue Breakdown
Recursion Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| License and Service | $43.88M | $39.68M | $10.00M |
| Grant | $699.00K | $162.00K | $178.00K |
Recursion Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: License and Service (98.43%), and Grant (1.57%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License and Service | $13.49M | $10.62M | $10.10M | $11.02M | $12.13M | $13.68M | $13.05M | $7.65M | $5.30M | $2.50M | $2.50M | $2.50M | $2.50M |
| Grant | $303.00K | $267.00K | $431.00K | $1.00K | - | - | $107.00K | $21.00K | $34.00K | $33.00K | $34.00K | $49.00K | $62.00K |
Recursion Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: License and Service (97.80%), and Grant (2.20%).
Recursion Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RXRX | Recursion Pharmaceuticals | $44.58M | $13.79M |
| VECT | VectivBio | $27.34M | $676.00K |
| RLAY | Relay Therapeutics | $25.55M | - |
| AFMD | Affimed | $8.28M | $155.00K |
| ABSI | Absci | $5.72M | $898.00K |
| CWBR | CohBar | - | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| AVRO | AVROBIO | - | - |
| CNSP | CNS Pharmaceuticals | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| SANA | Sana Bio | - | - |
| OCEA | Ocean Biomedical | - | - |
| IMMX | Immix Biopharma | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
| ENVB | Enveric Biosciences | - | - |
| EFTR | eFFECTOR Therapeutics | - | - |
RXRX Revenue FAQ
What is Recursion Pharmaceuticals’s yearly revenue?
Recursion Pharmaceuticals's yearly revenue for 2023 was $44.58M, representing an increase of 12.33% compared to 2022. The company's yearly revenue for 2022 was $39.68M, representing an increase of 296.81% compared to 2021. RXRX's yearly revenue for 2021 was $10M, representing an increase of 193.00% compared to 2020.
What is Recursion Pharmaceuticals’s quarterly revenue?
Recursion Pharmaceuticals's quarterly revenue for Q1 2024 was $13.79M, a 26.66% increase from the previous quarter (Q4 2023), and a 13.68% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $10.89M, a 7.81% increase from the previous quarter (Q3 2023), and a -20.36% decrease year-over-year (Q4 2022). RXRX's quarterly revenue for Q3 2023 was $10.1M, a -8.30% decrease from the previous quarter (Q2 2023), and a -22.61% decrease year-over-year (Q3 2022).
What is Recursion Pharmaceuticals’s revenue growth rate?
Recursion Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 345.75%, and for the last 5 years (2019-2023) was 2505.20%.
What are Recursion Pharmaceuticals’s revenue streams?
Recursion Pharmaceuticals's revenue streams in c 23 are License and Service, and Grant. License and Service generated $43.88M in revenue, accounting 98.43% of the company's total revenue, up 10.57% year-over-year. Grant generated $699K in revenue, accounting 1.57% of the company's total revenue, up 331.48% year-over-year.
What is Recursion Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Recursion Pharmaceuticals was License and Service. This segment made a revenue of $43.88M, representing 98.43% of the company's total revenue.